Thérapies ciblées : comment déterminer la cible ?

These last years numerous advances were realized in the treatment of the non small cell lung carcinoma by the discovery of biomarkers sensitive to targeted therapies. The highlighting of these biomarkers considerably modified the care of the samples by the pathologists. The latter also have to get acquainted with these new techniques in their laboratories. At the moment, only the highlighting of mutations of the EGFR and the translocation of ALK are integrated into the routine of the patient with advanced or metastatic NSCLC. But it is certain that in the future other biomarkers will be to test.